Vardenafil (Levitra/Staxyn) vs Alprostadil (Caverject/MUSE): Switching Between Them

How Vardenafil and Alprostadil Work Differently

Vardenafil blocks phosphodiesterase type 5 in penile smooth muscle, allowing cyclic GMP to accumulate and sustain an erection after sexual stimulation. Alprostadil binds prostaglandin E1 receptors directly on cavernosal smooth muscle cells, raising cyclic AMP and triggering relaxation independent of sexual arousal. These distinct mechanisms explain why alprostadil can rescue men who get no benefit from oral PDE5 inhibitors.

Vardenafil requires intact nitric-oxide signaling to work. Sexual stimulation triggers nitric oxide release from cavernosal nerve terminals, which activates guanylate cyclase to produce cyclic GMP. Vardenafil simply prevents the breakdown of that cGMP by inhibiting PDE5 1. When nerve damage or severe endothelial dysfunction blunts nitric oxide release, as happens in advanced diabetes or after radical prostatectomy, the drug has little substrate to preserve.

Alprostadil bypasses that pathway entirely. Injected into the corpus cavernosum or inserted as an intraurethral pellet, it activates adenylate cyclase through EP2 and EP4 prostanoid receptors, producing cyclic AMP. This second-messenger cascade relaxes smooth muscle without requiring any neural input 2. The 1996 Linet and Ogrinc trial published in the New England Journal of Medicine demonstrated that intracavernosal alprostadil produced erections sufficient for intercourse in 70% of men across a broad range of etiologies, including those who had failed oral agents available at the time 2.

The pharmacokinetic profiles also diverge. Vardenafil reaches peak plasma concentration in about 60 minutes (faster with the orally disintegrating Staxyn formulation) and has a half-life of 4-5 hours 3. Alprostadil injected intracavernosally acts within 5-20 minutes at the target tissue, with systemic exposure remaining low because 80% is metabolized on first pass through the lungs 4.

Clinical Efficacy: What the Trials Show

Vardenafil produces reliable erections in the majority of men with ED, and alprostadil rescues a large share of those who fail oral therapy. No randomized trial has compared these two drugs head to head, so clinicians rely on cross-trial data and guideline recommendations to sequence them.

The Porst et al. 2003 study enrolled 452 men with diabetes and erectile dysfunction across 70 centers. At the 20 mg dose, 72% reported improved erections on the Global Assessment Question, and the mean increase in IIEF erectile function domain score was 7.0 points above baseline versus 2.6 for placebo (P<0.001) 1. Diabetic ED is considered harder to treat because of combined neuropathy and vasculopathy, so these numbers represent a reasonable floor for vardenafil's performance in the broader ED population.

The Linet et al. 1996 NEJM trial is the landmark efficacy study for intracavernosal alprostadil. Among 296 men receiving active drug at home, 87% of injections resulted in an erection, and the mean duration of erection was approximately 46 minutes. Roughly 70% of men achieved erections adequate for intercourse across a dose range of 2.5-20 mcg 2. A Cochrane systematic review later confirmed that intracavernosal alprostadil is superior to placebo and comparable to combination intracavernosal regimens for men with refractory ED 5.

The MUSE intraurethral formulation is less invasive but also less effective. A key trial by Padma-Nathan et al. found that 65.9% of men achieved an erection sufficient for intercourse in-clinic, but only about 50% replicated that success at home 6. For men intimidated by injection, MUSE offers a middle ground, though with a meaningful efficacy trade-off.

When To Switch From Vardenafil to Alprostadil

The American Urological Association (AUA) 2018 guidelines on erectile dysfunction recommend oral PDE5 inhibitors as first-line pharmacotherapy and advise switching to intracavernosal injection therapy when at least one PDE5 inhibitor has failed at adequate dose and duration 7. The European Association of Urology (EAU) follows a similar algorithm, placing alprostadil ICI as the primary second-line option 8.

"Failure" of vardenafil means lack of response after at least 4-6 attempts at the maximum tolerated dose (20 mg for Levitra), taken on an empty stomach or with a low-fat meal, with adequate sexual stimulation, according to the AUA panel 7. Many men labeled as PDE5 non-responders simply used the drug incorrectly or took it with high-fat meals that delay absorption.

Specific clinical scenarios that push the switch include:

Post-radical prostatectomy ED is the most common. Even with bilateral nerve-sparing surgery, cavernosal nerve injury can be severe enough that insufficient nitric oxide reaches the penis. A study by Montorsi et al. found that early ICI alprostadil after prostatectomy preserved smooth muscle and improved later spontaneous recovery rates 9.

Severe diabetic vasculopathy with HbA1c persistently above 9% can make PDE5 inhibitors ineffective even at maximum dose, because both endothelial NO synthase expression and nerve function are compromised 1.

Men taking nitrates for angina cannot use any PDE5 inhibitor due to the risk of life-threatening hypotension. Alprostadil carries no such contraindication and is the default first-line pharmacotherapy in this population 7.

How To Make the Switch Safely

Transitioning from vardenafil to alprostadil requires in-office dose titration, patient education on injection technique, and a clear plan for monitoring. The process is not complicated, but skipping steps raises the risk of penile fibrosis or priapism.

The first injection should always happen in a clinical setting. The starting dose for intracavernosal alprostadil is typically 2.5 mcg in neurogenic ED (spinal cord injury, post-prostatectomy) and 10 mcg in vasculogenic ED 10. The clinician observes erectile response and monitors for prolonged erection. If the response is inadequate after 30 minutes, the dose can be increased by 2.5-5 mcg increments at the same visit. Target: the minimum dose that produces an erection firm enough for penetration lasting no longer than 60 minutes.

There is no required washout period between vardenafil and alprostadil. Vardenafil's half-life is 4-5 hours, so by 24 hours post-dose, the drug is effectively cleared. A man can take his last vardenafil dose one day and receive his first alprostadil titration injection the next 3.

Patient training covers sterile technique, injection angle (90 degrees at the 10-o'clock or 2-o'clock position on the penile shaft), alternating sides, and recognizing priapism. If an erection persists beyond 4 hours, the patient must seek emergency aspiration and phenylephrine irrigation. The Linet trial reported a 1.3% rate of prolonged erection per patient and a 0.4% rate requiring intervention 2.

For men unwilling to inject, MUSE is the intermediate step. The intraurethral pellet is inserted via a small applicator after urination. Dosing starts at 250 mcg and can be titrated up to 1 to 000 mcg 6. Efficacy is lower than ICI, but patient acceptability is higher.

Side Effect Profiles Compared

Vardenafil's side effects are systemic and generally mild. Alprostadil's are local and occasionally require medical intervention. Understanding this contrast matters for the switching decision.

Vardenafil's most reported adverse events from pooled trial data include headache (15%), flushing (11%), nasal congestion (9%), and dyspepsia (4%) 3. Rare but clinically significant effects include QTc prolongation, which led to a label warning against use with class IA or III antiarrhythmics, and non-arteritic anterior ischemic optic neuropathy (NAION), reported at rates too low to quantify precisely but flagged in post-marketing surveillance 11.

Alprostadil ICI's side-effect profile is dominated by penile pain, which occurs in 30-50% of injections but typically diminishes over weeks of use 2. Penile fibrosis or Peyronie-like plaques develop in approximately 5-7% of long-term users, a risk that increases with poor injection technique or repeated injection at the same site 10. Bruising and hematoma at the injection site occur in roughly 8-10% of patients. Hypotension is rare with ICI because systemic absorption is minimal.

MUSE shares the penile pain issue (24-32% of administrations) and can cause urethral burning or minor bleeding. It also carries a 3.3% rate of symptomatic hypotension, a concern not seen with ICI 6.

Switching Back: Alprostadil to Vardenafil

The reverse switch is less common but not unusual. Some men initially started on alprostadil (because of nitrate use, for example) later discontinue nitrates and become candidates for oral therapy.

If the contraindication that prevented PDE5 inhibitor use has resolved, restarting vardenafil is straightforward. The AUA guidelines note that PDE5 inhibitors should be re-trialed at standard starting doses (10 mg for vardenafil) with dose escalation as needed 7. A nitrate-free interval of at least 24 hours must be confirmed before the first vardenafil dose.

Some men on long-term alprostadil ICI develop improved spontaneous erectile function over time, particularly after prostatectomy as nerves recover. In these cases, periodic trials of vardenafil can serve as a "step-down" test. Goldstein et al. described this strategy in post-prostatectomy penile rehabilitation, where early ICI is followed by transition to PDE5 inhibitors once nerve recovery permits 12.

Combination use is also possible. Low-dose alprostadil ICI with a PDE5 inhibitor can produce synergistic effects through complementary cyclic nucleotide pathways. A small study by McMahon et al. showed that the combination of ICI alprostadil with oral sildenafil improved rigidity in men who responded inadequately to either agent alone 13. Though this study used sildenafil rather than vardenafil, the PDE5-inhibitor class effect makes the principle transferable under physician supervision.

Cost and Access Considerations

Price often influences whether a patient stays on vardenafil or transitions to alprostadil, because insurance coverage for ED medications varies widely and many plans exclude them entirely.

Generic vardenafil tablets became available in the United States after patent expiry and typically cost $2-8 per tablet at retail pharmacies with discount coupons. Brand-name Levitra, when stocked, runs $40-60 per tablet. Staxyn (orally disintegrating vardenafil) remains brand-only and costs approximately $45-55 per tablet 11.

Caverject Impulse (alprostadil ICI) costs $40-75 per single-use injection kit without insurance. The cost per month depends on injection frequency: at two uses per week, a patient may spend $320-600 monthly. MUSE pellets range from $30-55 per dose. Some specialty and compounding pharmacies offer alprostadil in multi-dose vials (trimix or bimix compounded formulations including alprostadil, papaverine, and phentolamine) at $80-150 per vial supplying 10-20 injections, which significantly reduces per-use cost.

Medicare Part D and most commercial plans classify ED drugs as "lifestyle" and exclude them. The Veterans Health Administration (VA) does cover both vardenafil and alprostadil for service-connected ED. Patients should check formulary status and prior-authorization requirements with their specific plan before assuming coverage 7.

Patient Selection: Which Drug Fits Which Man

Choosing between vardenafil and alprostadil is rarely about which drug is "better" in the abstract. The decision follows a stepwise algorithm driven by the patient's anatomy, comorbidities, contraindications, and tolerance for injection.

Vardenafil is the appropriate starting point for any man with ED who has no contraindications to PDE5 inhibitors. That covers the vast majority. Oral therapy is simpler, less invasive, and carries a favorable safety profile across decades of post-marketing data.

Alprostadil becomes the right choice when:

• The patient has failed adequate trials of two or more PDE5 inhibitors (vardenafil, sildenafil, tadalafil, avanafil) at maximum dose.
• Nitrate therapy for coronary artery disease makes all PDE5 inhibitors contraindicated.
• Severe cavernosal nerve injury (radical prostatectomy without nerve sparing, pelvic trauma) eliminates the nitric-oxide signal that PDE5 inhibitors depend on.
• The patient has a penile prosthesis revision or anatomical issue favoring direct smooth muscle relaxation.

As the EAU 2020 guidelines state: "Intracavernosal alprostadil is the most effective non-surgical treatment for erectile dysfunction across all etiologies" 8. That effectiveness comes at the cost of an injection, which roughly 50% of patients offered ICI ultimately decline.

The recommended frequency cap for alprostadil ICI is no more than three injections per week, with at least 24 hours between injections, to minimize fibrosis risk 10.